Skip to main content
Equibles

Lavina Talukdar

Analyst

Corporate Communications

Moderna, Inc. (MRNA)

Board Member

Monopar Therapeutics (MNPR)

Equibles does not estimate personal net worth.

About Lavina Talukdar

Lavina Talukdar is recorded as Analyst at Corporate Communications and Board Member at Monopar Therapeutics (MNPR) since January 1, 2025. The newest filing on record that lists Lavina Talukdar as Board Member at Monopar Therapeutics (MNPR) is dated April 30, 2026. Monopar Therapeutics reported in an 8-K filed February 24, 2025 that Lavina Talukdar was appointed Board, effective February 21, 2025. Lavina Talukdar has spoken on 23 earnings calls across 1 company, most recently for Moderna, Inc. on July 31, 2026. Moderna, Inc. is classified in the Biotechnology industry within the Healthcare sector. Monopar Therapeutics is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Moderna, Inc. includes Stéphane Bancel (CEO and Board Member), Noubar Afeyan (Chairman and Board Member), David W. Meline (CFO) and 7 others.

“On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.”
Monopar Therapeutics Form 8-K, filed February 24, 2025 · Read the filing

Lavina Talukdar on recent calls

“Good morning, everyone. and thank you for joining us on today's call to discuss Moderna's second quarter 2026 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investor section of our website.”
Head of Investor Relations, Moderna Q2 Earnings call ·
“Good morning, everyone, and thank you for joining us today to discuss Moderna's first quarter 2026 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investor section of our website.”
Head of Investor Relations, Moderna, Inc. Q1 FY2026 Earnings Call ·
“Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's fourth quarter 2025 financial results and business updates. You can access the press release issued this morning, as well as the slides that we'll be reviewing, by going to the Investors section of our website.”
Head of Investor Relations, Moderna, Inc. Q4 FY2025 Earnings Call ·
“So to start here, maybe frame for us how you see the company positioned today.”
Head of Investor Relations, Moderna, Inc. Q3 FY2025 Earnings Call ·
“Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's first quarter 2025 financial results and business updates. You can access the press release issued this morning as well as the slides that we will be reviewing by going to the Investors section of our website.”
Head of Investor Relations, Moderna, Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Moderna, Inc.

Leadership on record at Monopar Therapeutics

Recent activity

Show 12 earlier activities